

Santhera Pharmaceuticals Holding AG (SANN) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/S07038AE3BEEN.html>

Date: May 2021

Pages: 54

Price: US\$ 125.00 (Single User License)

ID: S07038AE3BEEN

Abstracts

Santhera Pharmaceuticals Holding AG (SANN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Santhera Pharmaceuticals Holding AG (Santhera) develops and markets novel pharmaceutical products indicated for patients with mitochondrial and neuromuscular diseases. It specifically focuses on the area of neuromuscular and ophthalmological conditions. The company's lead product candidate, Raxone is developed for the treatment of Leber's hereditary optic neuropathy (LHON). Raxone is investigated for other diseases such as Duchenne muscular dystrophy and primary progressive multiple sclerosis. Santhera's pipeline also includes other compounds, namely, omigapil for congenital muscular dystrophies. It operates through its subsidiaries in Switzerland, Germany, Canada, Finland and the US. Santhera is headquartered in Pratteln, Switzerland.

Santhera Pharmaceuticals Holding AG Key Recent Developments

Apr 29,2021: Santhera Reports 2020 Annual Results

Apr 20,2021: Santhera Reports Interim Results on Convertible Bond Exchange Offer

Mar 18,2021: Santhera's Shareholders Approve all Board Proposals at Today's Extraordinary General Meeting

Feb 16,2021: Santhera announces corporate update and proposal to strengthen capital

structure

Sep 08,2020: Santhera announces financial results for the first half-year 2020 and updates on corporate progress

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Santhera Pharmaceuticals Holding AG - Key Facts
Santhera Pharmaceuticals Holding AG - Key Employees
Santhera Pharmaceuticals Holding AG - Key Employee Biographies
Santhera Pharmaceuticals Holding AG - Major Products and Services
Santhera Pharmaceuticals Holding AG - History
Santhera Pharmaceuticals Holding AG - Company Statement
Santhera Pharmaceuticals Holding AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Santhera Pharmaceuticals Holding AG - Business Description
Geographical Segment: EU
Performance
Geographical Segment: Rest of World
Performance
R&D Overview
Santhera Pharmaceuticals Holding AG - Corporate Strategy
Santhera Pharmaceuticals Holding AG - SWOT Analysis
SWOT Analysis - Overview
Santhera Pharmaceuticals Holding AG - Strengths
Santhera Pharmaceuticals Holding AG - Weaknesses
Santhera Pharmaceuticals Holding AG - Opportunities
Santhera Pharmaceuticals Holding AG - Threats
Santhera Pharmaceuticals Holding AG - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios

Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021

Santhera Pharmaceuticals Holding AG, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Apr 29, 2021: Santhera Reports 2020 Annual Results

Apr 20, 2021: Santhera Reports Interim Results on Convertible Bond Exchange Offer

Mar 18, 2021: Santhera’s Shareholders Approve all Board Proposals at Today’s Extraordinary General Meeting

Feb 16, 2021: Santhera announces corporate update and proposal to strengthen capital structure

Sep 08, 2020: Santhera announces financial results for the first half-year 2020 and updates on corporate progress

Sep 03, 2020: Santhera obtains exclusive licence to DMD drug vamorolone

Jul 20, 2020: Santhera to join six Swiss exchange life science industry indices

Apr 27, 2020: Santhera explores lonodelestat to treat ARDS in Covid-19 patients

Mar 24, 2020: Santhera reports 2019 annual results and highlights pipeline progress in Duchenne Muscular Dystrophy

Jan 27, 2020: Santhera reports net revenues 2019 and highlights pipeline progress

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Santhera Pharmaceuticals Holding AG, Key Facts
Santhera Pharmaceuticals Holding AG, Key Employees
Santhera Pharmaceuticals Holding AG, Key Employee Biographies
Santhera Pharmaceuticals Holding AG, Major Products and Services
Santhera Pharmaceuticals Holding AG, History
Santhera Pharmaceuticals Holding AG, Subsidiaries
Santhera Pharmaceuticals Holding AG, Key Competitors
Santhera Pharmaceuticals Holding AG, Ratios based on current share price
Santhera Pharmaceuticals Holding AG, Annual Ratios
Santhera Pharmaceuticals Holding AG, Annual Ratios (Cont...1)
Santhera Pharmaceuticals Holding AG, Annual Ratios (Cont...2)
Santhera Pharmaceuticals Holding AG, Interim Ratios
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Santhera Pharmaceuticals Holding AG, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Santhera Pharmaceuticals Holding AG, Performance Chart (2016 - 2020)

Santhera Pharmaceuticals Holding AG, Ratio Charts

Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Santhera Pharmaceuticals Holding AG, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Santhera Pharmaceuticals Holding AG (SANN) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/S07038AE3BEEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S07038AE3BEEN.html>